Evidence map›Paper›PMID 34377989›Full record

ArticleNeuro-oncology advances

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.

Benjamin M Ellingson, Kunal Patel, Chencai Wang, Catalina Raymond, Andrew Brenner, John F de Groot, Nicholas A Butowski, Leor Zach, Jian L Campian, Jacob Schlossman and 7 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02511405 (A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02511405 phase3completednot on this map

A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma

TypeinterventionalSponsorVascular Biogenics Ltd. operating as VBL TherapeuticsRan2015 to 2018Enrolled252ConditionsGlioblastomaArmsVB-111 + bevacizumab, Bevacizumab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-2764-6640
Kunal PatelUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Chencai WangUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Andrew BrennerUniversity of Texas Health San Antonio Cancer Center, San Antonio, Texas, USA.
John F de GrootDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas A ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Leor ZachOncology Institute, Chaim Sheba Medical Center, Tel HaShomer, Israel.
Jian L CampianDivision of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-5317-8481
Jacob SchlossmanUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Shan RizviUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Yael C CohenVBL Therapeutics, Modi'in, Israel.
Noa Lowenton-SpierVBL Therapeutics, Modi'in, Israel.
Tamar Rachmilewitz MineiVBL Therapeutics, Modi'in, Israel.
Shifra Fain ShmueliVBL Therapeutics, Modi'in, Israel.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Timothy F CloughesyUCLA Neuro Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · USVascular Biogenics (Israel) · ILCenter for Neuro-Oncology · USSheba Medical Center · ILThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USWashington University in St. Louis · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

backgroundEvidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current study confirms these findings in a large, randomized phase III clinical trial.

methodsPatients with rGBM were enrolled in a phase III randomized (1:1), controlled trial (NCT02511405) to compare the efficacy and safety of bevacizumab (BV) versus BV in combination with ofranergene obadenovec (BV+VB-111), an anti-cancer viral therapy. In 170 patients with diffusion MRI available, pretreatment enhancing tumor volume and ADC histogram analysis were used to phenotype patients as having high (>1.24 µm

resultsBaseline tumor volume (

conclusionBaseline diffusion MRI and tumor volume are independent imaging biomarkers of OS in rGBM treated with BV or BV+VB-111.

Indexed as

anti-VEGF therapybevacizumabdiffusion MRIimaging biomarkerrecurrent GBMVB-111

Identifiers

PMID34377989
PMCPMC8350152
OpenAlexW3177211148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.